

Supplemental Table S1. The correlations between percent reduction of psoriasis area and severity index (PASI) at week 12 versus age, body mass index (BMI), disease duration, baseline values of PASI or laboratory parameters

| | Whole TNF- α inhibitors (55) | | IFX (28) | | ADA (15) | | CZP (12) | |
|-----------------------|--|----------|------------|----------|------------|----------|------------|----------|
| Background factors | <i>rho</i> | <i>p</i> | <i>rho</i> | <i>p</i> | <i>rho</i> | <i>p</i> | <i>rho</i> | <i>p</i> |
| Age | -0.202 | 0.138 | -0.166 | 0.399 | -0.388 | 0.153 | -0.0561 | 0.862 |
| BMI | -0.0308 | 0.825 | 0.0707 | 0.721 | -0.486 | 0.0779 | 0.063 | 0.846 |
| Disease duration | -0.207 | 0.13 | -0.231 | 0.236 | -0.204 | 0.466 | -0.342 | 0.277 |
| Baseline PASI | 0.242 | 0.0751 | 0.266 | 0.171 | 0.182 | 0.516 | 0.125 | 0.699 |
| Baseline CRP | 0.136 | 0.322 | 0.0861 | 0.663 | 0.115 | 0.684 | 0.384 | 0.217 |
| Baseline NLR | 0.00791 | 0.954 | -0.178 | 0.365 | 0.333 | 0.226 | 0.413 | 0.182 |
| Baseline MLR | -0.158 | 0.249 | -0.167 | 0.396 | -0.143 | 0.611 | -0.179 | 0.579 |
| Baseline PLR | -0.0337 | 0.807 | -0.178 | 0.366 | 0.284 | 0.304 | -0.102 | 0.753 |

Correlations between variables were examined using Spearman's correlation coefficients.

TNF- α , tumor necrosis factor- α ; IFX, infliximab; ADA, adalimumab; CZP, certolizumab pegol;

NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio;

CRP, C-reactive protein